Ra Medical Systems to Showcase Pharos, Optimized Dermatology Excimer Laser at Two Upcoming Dermatology Conferences
January 23 2020 - 6:50AM
Business Wire
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company
focusing on commercializing excimer laser systems to treat vascular
and dermatological diseases, announces it will be showcasing its
Pharos, Optimized Dermatology Excimer Laser at two upcoming
dermatology conferences.
- 16th Annual Maui Derm for Dermatologists 2020 being held
at the Grand Wailea Maui Resort in Wailea, Maui on January 25-29.
The conference presents healthcare providers with in-depth material
covering a wide array of medical and cosmetic topics in
dermatology. More information is available here.
- Skin Disease Education Foundation's 44th Annual Hawaii
Dermatology Seminar being held at the Hyatt Regency, in
Lahaina, Maui on February 16-21. The seminar explores the latest
advances in the treatment and management of common and complex
diseases of the skin including cutting-edge, innovative and
evolving issues relevant to practicing physicians and healthcare
providers who treat diseases of the skin. More information is
available here.
“We are pleased to showcase the Pharos, Optimized excimer laser
to the many dermatologists and healthcare providers attending these
key industry conferences,” said Andrew Jackson, Ra Medical Systems
CFO and Interim CEO. “This next-generation Pharos laser was
designed to enhance physician and patient experiences with faster
treatment times and extended peak performance. I’m pleased to
report that the Pharos, Optimized laser has been received
positively in the six months since its commercial
introduction.”
About Pharos Excimer Laser
Pharos is a powerful 308 nm ultraviolet-B excimer laser used by
physicians as a tool to treat the following chronic skin diseases:
psoriasis, vitiligo, atopic dermatitis, and leukoderma. Ra Medical
Systems has FDA clearance and CE Mark clearance to market Pharos
for use in the treatment of those skin conditions, as well as
market clearance in China. Pharos is the only excimer laser to
feature integrated adjustable aiming and laser beams to deliver
precisely targeted treatments that spare healthy tissue. The
laser’s small footprint enables it to fit into any treatment room,
saving valuable floor space.
About Ra Medical Systems
Ra Medical Systems commercializes excimer lasers and catheters
for the treatment of vascular and dermatological diseases. In May
2017, the DABRA laser system and single-use DABRA catheter received
FDA 510(k) clearance in the U.S. as a device for crossing chronic
total occlusions, or CTOs, in patients with symptomatic
infrainguinal lower extremity vascular disease with an intended use
for ablating a channel in occlusive peripheral vascular disease.
Pharos excimer laser system is FDA-cleared and is used as a tool in
the treatment of psoriasis, vitiligo, atopic dermatitis, and
leukoderma. DABRA and Pharos are both based on Ra Medical’s core
excimer laser technology platform and deploy similar mechanisms of
action. Ra Medical manufactures DABRA and Pharos excimer lasers and
catheters in a 32,000-square-foot facility located in Carlsbad,
Calif. The vertically integrated facility is ISO 13485 certified
and is licensed by the state of California to manufacture sterile,
single-use catheters in controlled environments.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Ra Medical’s future financial or operating performance. In some
cases, you can identify forward-looking statements because they
contain words such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “could,” “intends,” “target,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these words or other similar terms or
expressions that concern Ra Medical’s future expectations,
strategy, plans or intentions. Forward-looking statements in this
press release include, but are not limited to, statements regarding
Ra Medical’s business strategy, including the continued adoption of
Pharos, Optimized. Ra Medical’s expectations and beliefs regarding
these matters may not materialize, and actual results in future
periods are subject to risks and uncertainties that could cause
actual results to differ materially from those projected or implied
by such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, challenges inherent in
developing, manufacturing, launching, marketing, and selling new
products; risks associated with acceptance of DABRA and Pharos and
procedures performed using such devices by physicians, payors, and
other third parties; development and acceptance of new products or
product enhancements; clinical and statistical verification of the
benefits achieved via the use of Ra Medical’s products; the results
from our clinical trials, which may not support intended
indications or may require Ra Medical to conduct additional
clinical trials or modify ongoing clinical trials; challenges
related to commencement, patient enrollment, completion, an
analysis of clinical trials; Ra Medical’s ability to manage
operating expenses; Ra Medical’s ability to effectively manage
inventory; Ra Medical’s ability to recruit and retain management
and key personnel; Ra Medical’s need to comply with complex and
evolving laws and regulations; intense and increasing competition
and consolidation in Ra Medical’s industry; the impact of rapid
technological change; costs and adverse results in any ongoing or
future legal proceedings; adverse outcome of regulatory
inspections; and the other risks and uncertainties described in Ra
Medical’s news releases and filings with the Securities and
Exchange Commission. Information on these and additional risks,
uncertainties, and other information affecting Ra Medical’s
business and operating results is contained in Ra Medical’s Annual
Report on Form 10-K for the year ended December 31, 2018 and in its
other filings with the Securities and Exchange Commission. The
forward-looking statements in this press release are based on
information available to Ra Medical as of the date hereof, and Ra
Medical disclaims any obligation to update any forward-looking
statements, except as required by law.
Ra Medical investors and others should note that we announce
material information to the public about the company through a
variety of means, including our website (www.ramed.com), our
investor relations website (https://ir.ramed.com/), press releases,
SEC filings, and public conference calls in order to achieve broad,
non-exclusionary distribution of information to the public and to
comply with our disclosure obligations under Regulation FD. We
encourage our investors and others to monitor and review the
information we make public in these locations as such information
could be deemed to be material information. Please note that this
list may be updated from time to time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200123005176/en/
At the Company: Jeffrey Kraws
President, Ra Medical Systems 760-496-9008 jkraws@ramed.com
Investors and Media: LHA Investor
Relations Jody Cain / Kevin McCabe 310-691-7100 jcain@lhai.com / kmccabe@lhai.com
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Apr 2023 to Apr 2024